HB134 / Huahui Health - LARVOL DELTA

A T cell engager (TCE), HB134, targeting LILRB4 and CD3, exhibits potent anti-tumor activity with a favorable safety profile for monocytic AML (AACR 2025) - "HB134, a TCE designed to engage T cells via CD3 and specifically target LILRB4, exhibits potent anti-tumor activity and favorable PK and safety profiles, positioning HB134 as a promising therapeutic candidate for treating LILRB4-positive monocytic AML."

Clinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • IL6 • LILRB4 • TNFA